177Lu-PSMA: Single Time-Point Dosimetry Tied to Treatment Response in mCRPC
177Lu-PSMA: Single Time-Point Dosimetry Tied to Treatment Response in mCRPC

Scott Tagawa, MD, and Valentina Marulanda Corzo, MD, of Weill Cornell Medicine, discuss their work on a study presented at the SNMMI 2025 Annual Meeting that examined the use of single time-point SPECT/CT dosimetry for 177Lu-PSMA targeted radionuclide therapy in patients with mCRPC.

Dr. Marulanda Corzo describes the two different time points that were studied, as well as how future research should be focused on precision medicine and personalized therapy.

Advertisement

Latest News

15-Gene Prognostic Score Links Worse PFS to Sunitinib, Everolimus Treatment for Patients With Metastatic ccRCC
15-Gene Prognostic Score Links Worse PFS to Sunitinib, Everolimus Treatment for Patients With Metastatic ccRCC
Emily MenendezAdvanced Renal Cell Carcinoma | July 18, 2025
A new evaluation of several trials has shed light on the prognostic performance of the 15G score in patients with mccRCC.
Identifying the Relationship Among DDR Gene Alterations, Molecular Subtypes, and Survival Outcomes in Metastatic UC
Identifying the Relationship Among DDR Gene Alterations, Molecular Subtypes, and Survival Outcomes in Metastatic UC
Jessica GangaAdvanced Urothelial Carcinoma | July 18, 2025
Researchers evaluated the link between DDR alterations, molecular subtypes and survival benefits in mUC using Phase 3 data.
When PSMA PET/CT Is Negative: Using 18F-Fluciclovine in Biochemical Recurrence of Prostate Cancer
When PSMA PET/CT Is Negative: Using 18F-Fluciclovine in Biochemical Recurrence of Prostate Cancer
Nadine Mallak, MDProstate Cancer Diagnostics | July 15, 2025
Dr. Nadine Mallak talks about 18F-fluciclovine to detect disease in BCR of prostate cancer when the standard of care fails.
Combination Enzalutamide/Leuprolide Shows Promise in Overall Survival in Patients With nmHSPC, High-Risk Biochemical Recurrence
Combination Enzalutamide/Leuprolide Shows Promise in Overall Survival in Patients With nmHSPC, High-Risk Biochemical Recurrence
Jessica GangamHSPC | July 15, 2025
Phase 3 EMBARK trial results show promising survival benefits of combination therapy in patients with nmHSPC.
Margin Matters: The Pathology Advantage of En Bloc TURBT
Margin Matters: The Pathology Advantage of En Bloc TURBT
Michael Ahdoot, MDNon-Muscle Invasive Urothelial Carcinoma | July 15, 2025
Drs. Ahdoot and Yerram weigh how to approach tumors located in challenging areas, and the role of detrusor muscle sampling.
En Bloc TURBT and Surgical Evolution in Bladder Cancer
En Bloc TURBT and Surgical Evolution in Bladder Cancer
Michael Ahdoot, MDNon-Muscle Invasive Urothelial Carcinoma | July 15, 2025
Drs. Ahdoot and Yerram discuss the fundamental reasons for adopting en bloc resection in bladder cancer surgery.
Utility of PSMA PET/CT in Prostate Cancer Biochemical Failure
Utility of PSMA PET/CT in Prostate Cancer Biochemical Failure
Brittany Miles, MDProstate Cancer Diagnostics | July 15, 2025
Dr. Miles highlights the dilemma of managing PC with BCR after prostatectomy but no visible disease on standard imaging.
Next-Line Thinking: Optimizing Treatment Beyond ARPIs in mCRPC
Next-Line Thinking: Optimizing Treatment Beyond ARPIs in mCRPC
Scott Sellinger, MDProstate Cancer | July 14, 2025
The panel discusses the evolving treatment landscape for mCRPC, focusing on the role of RLTs and PARP inhibitors.
Upfront Matters: Navigating Treatment Intensification in mCSPC
Upfront Matters: Navigating Treatment Intensification in mCSPC
Scott Sellinger, MDProstate Cancer | July 14, 2025
The panel discusses treatment intensification strategies for mCSPC, emphasizing the shift toward doublet and triplet therapy.
Delaying ADT, Preserving Quality: Smarter Choices in Metastatic Prostate Cancer
Delaying ADT, Preserving Quality: Smarter Choices in Metastatic Prostate Cancer
Scott Sellinger, MDProstate Cancer | July 14, 2025
The panel discusses the growing role of advanced molecular imaging and genomic testing in prostate cancer care.
The Modern Landscape of Advanced Prostate Cancer: Diagnosis, Risk, and Imaging
The Modern Landscape of Advanced Prostate Cancer: Diagnosis, Risk, and Imaging
Scott Sellinger, MDProstate Cancer | July 14, 2025
The panel begins with the landscape of advanced PC care, emphasizing accurate categorization of disease stage and burden.
Bevacizumab and Erlotinib Combination May Help HLRCC-Linked Papillary RCC
Bevacizumab and Erlotinib Combination May Help HLRCC-Linked Papillary RCC
Jessica GanganccRCC | July 11, 2025
Phase 2 trial examines efficacy and response of bevacizumab/erlotinib for treatment of patients with rare subtypes of RCC.
Advertisement
Advertisement
Editorial Advisory Board
Brian Rini, MD, FASCO
Brian Rini, MD, FASCOEditor | Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center
Thomas Powles, MBBS, MRCP, MD
Thomas Powles, MBBS, MRCP, MDEditor | Director, Barts Cancer Centre at St. Bartholomew's Hospital
Katy Beckermann, MD, PhD
Katy Beckermann, MD, PhDEditor | Medical Director of GU Clinical Research at Tennessee Oncology
Christopher Wallis, MD, PhD, FRCSC
Christopher Wallis, MD, PhD, FRCSCAssistant Professor of Urology | University of Toronto
Akhil Abraham Saji, MD
Akhil Abraham Saji, MDEditor | Urologist at Swedish Health Services
David Ambinder, MD
David Ambinder, MDEditor | Urology Resident at New York Medical College/Westchester Medical Center

The Uromigos Live and Unplugged 2024

The Uromigos Live & Unplugged 2024
The Uromigos Live & Unplugged 2024

The Uromigos Live & Unplugged 2024 took place September 27-29 in Nashville, Tennessee.

This meeting was the third annual in-person event hosted by Thomas Powles, MD, and Brian Rini, MD, FASCO, in partnership with Mashup Media, featuring expert panels and audience discussion around the latest data in genitourinary oncology and vision for the future.

Expert Interviews

Teaching TURBT Over 5G: Integrating XR Headsets Into Urologic Practice
Teaching TURBT Over 5G: Integrating XR Headsets Into Urologic Practice
Evan Kovac, MDProstate Cancer | May 19, 2025
Dr. Evan Kovac speaks about his pioneering work with extended reality display technology in urologic surgery and education.
Bladder Cancer Without Cystectomy: Dr. Alexandre Zlotta on the Maturation of Trimodality Therapy
Bladder Cancer Without Cystectomy: Dr. Alexandre Zlotta on the Maturation of Trimodality Therapy
Alexandre Zlotta, MDMuscle Invasive Urothelial Carcinoma | May 15, 2025
Dr. Zlotta discusses the current state and future of bladder-sparing therapy in MIBC, including how to best select patients.
From VEGF to HIF-2 Targeting Drugs: Dr. James Brugarolas’ Journey to Transforming Kidney Cancer Treatment
From VEGF to HIF-2 Targeting Drugs: Dr. James Brugarolas’ Journey to Transforming Kidney Cancer Treatment
James “Jim” Brugarolas, MD, PhDRenal Cell Carcinoma | April 22, 2025
Dr. Brugarolas reflects on his lab's role in developing HIF-2 inhibitors and his ongoing work to improve patient outcomes.
Bladder-Sparing Innovations in MIBC: Dr. Elizabeth Plimack on the RETAIN Approach and Its Future
Bladder-Sparing Innovations in MIBC: Dr. Elizabeth Plimack on the RETAIN Approach and Its Future
Elizabeth Plimack, MD, MS, FASCOMuscle Invasive Urothelial Carcinoma | June 25, 2025
Dr. Plimack details RETAIN, from early findings with neoadjuvant ddMVAC to the evolution of RETAIN-1 and RETAIN-2.
Precision in Prostate Cancer: Dr. Amir Lebastchi on Tailoring Focal Therapy for Optimal Outcomes
Precision in Prostate Cancer: Dr. Amir Lebastchi on Tailoring Focal Therapy for Optimal Outcomes
Akhil Abraham Saji, MDLocalized | June 25, 2025
Drs. Saji and Lebastchi explore focal therapy, covering its historical evolution, techniques, and energy modalities.
Ahmed E. Ghazi – Revolutionizing and Scaling Surgical Training Through Simulation Models
Ahmed E. Ghazi – Revolutionizing and Scaling Surgical Training Through Simulation Models
David Ambinder, MDLocalized | June 25, 2025
Dr. Ghazi is recognized as a pioneer in patient-specific surgical simulation, using state-of-the-art techniques in surgery.

Conference Coverage

Live meeting highlights

177Lu-PSMA: Single Time-Point Dosimetry Tied to Treatment Response in mCRPC
Valentina Marulanda Corzo, MDRLT | July 18, 2025
Drs. Tagawa and Marulanda Corzo discuss the use of single time-point SPECT/CT dosimetry for 177Lu-PSMA targeted RLT.
View More
When PSMA PET/CT Is Negative: Using 18F-Fluciclovine in Biochemical Recurrence of Prostate Cancer
Nadine Mallak, MDProstate Cancer Diagnostics | July 15, 2025
Dr. Nadine Mallak talks about 18F-fluciclovine to detect disease in BCR of prostate cancer when the standard of care fails.
View More
Utility of PSMA PET/CT in Prostate Cancer Biochemical Failure
Brittany Miles, MDProstate Cancer Diagnostics | July 15, 2025
Dr. Miles highlights the dilemma of managing PC with BCR after prostatectomy but no visible disease on standard imaging.
View More
Can PSMA PET Imaging Predict Lu-PSMA Outcomes?
Koichiro Kimura, MD, PhDRLT | July 8, 2025
Dr. Kimura shares insights on PSMA PET/CT metrics and their potential role in guiding treatment decisions for mCRPC.
View More

Video Insights

Clinical discussions with experts in the field

Network Websites

Blood Cancers Today provides hematologists and oncologists with news, education, and research relevant to their patients and practices. Featuring the latest clinical updates from all facets of the specialty, it offers thought-provoking insights and exclusive interviews from experts in the field.

MashupMD is an innovative medical news and social media aggregator. The platform is optimized to deliver rapid access to the latest headlines in health care and collections of key medical content based on what health care professionals around the world are reading and sharing.

Cancer Nursing Today delivers critical news, research, and commentary to support oncology nurses throughout their education and careers. Its goal is to advance oncology treatments and care practices and promote the nurse’s role in enhanced patient outcomes and quality of life.

DocWire News is a leading source of medical industry news for health care professionals, featuring breaking news, expert commentary, research analysis, and conference highlights. It covers a comprehensive range of clinical specialties, including cardiology, oncology, neurology, and more.

Urban Health Today is the leading independent news source that provides urban health care professionals with relevant research and policy developments that impact patients and their practices. Its coverage focuses on clinical, social, and environmental health disparities.

Powered by DocWire News

GI Oncology Now is the leading medical news resource for practicing oncologists and health care providers treating gastrointestinal malignancies, offering the latest study data and research breakthroughs related to colorectal, gastric, liver, pancreatic, and esophageal cancers.

Heme Today produces the latest news and research for hematologists and oncologists focused on blood disorders such as clotting, red and white blood cell, and iron disorders, including conference highlights, late-breaking research, interviews with leaders in the field, and more.

A medical news property for practicing oncologists treating lung malignancies, Lung Cancers Today features breaking news, commentary, expert interviews, and data analysis to inform providers on the latest research and most effective clinical practices in the lung cancers space.

Nephrology Times delivers the latest news in nephrological treatments and technologies, curating content from clinical trials, conference highlights, and perspectives from key opinion leaders, with the goal of better informing care decisions and improving patient outcomes.

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    About Us

    Contributors and Partners

    Editorial Policy

    Advertising

    Connect

    eNewsletters

    Calendar

    Contact Us

    Contribute

    Our Network

    MashupMD

    Cancer Nursing Today

    Urban Health Today

    Blood Cancers Today

    DocWire News

    © 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy |